Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 250,000 shares, an increase of 189.4% from the December 31st total of 86,400 shares. Based on an average trading volume of 3,070,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 5.8% of the company’s stock are sold short.
Bio-Path Price Performance
BPTH traded down $0.03 during trading on Wednesday, reaching $0.81. 50,984 shares of the stock were exchanged, compared to its average volume of 177,183. The stock’s 50 day moving average price is $0.89 and its two-hundred day moving average price is $1.08. Bio-Path has a twelve month low of $0.59 and a twelve month high of $9.99.
Analyst Upgrades and Downgrades
Separately, StockNews.com assumed coverage on Bio-Path in a research note on Wednesday. They issued a “sell” rating for the company.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Articles
- Five stocks we like better than Bio-Path
- 3 Stocks to Consider Buying in October
- 3 Steel Stocks Soaring After Tariff Announcements
- Manufacturing Stocks Investing
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- Stock Market Upgrades: What Are They?
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
